Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 9/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL832849 | 0.87 | EPHX1 (0.46) | ALDH1A1CYP1A2CYP3A4CYP2C19SLC7A5 | |
| SCHEMBL6383255 | 0.82 | ESR2 (0.83) | ESR1ESR2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL7452482 | 0.82 | EPHX1 (0.42) | MEN1ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL11754323 | 0.78 | LDHA (0.51) | MEN1ALDH1A1CYP1A2CYP2C19KMT2A | |
| SCHEMBL983099 | 0.77 | SLC6A2 (0.55) | ESR1ESR2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL163773 | 0.75 | ESR1 (0.55) | ESR1ESR2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL20425314 | 0.75 | ESR1 (0.55) | ESR1ESR2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL1838937 | 0.75 | ESR1 (0.50) | ESR1ESR2MEN1ALDH1A1CYP1A2 | |
| Bicarbonate SCHEMBL28093815 | 0.74 | ESR1 (0.53) | ESR1ESR2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL9498596 | 0.73 | ESR1 (0.60) | ESR1ESR2SLC7A5FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265146-B2 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2007-09-04 | — | — | US | claimed |
| US-20050187284-A1 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2005-08-25 | — | — | US | claimed |
| EP-1330430-A2 | INTEGRIN RECEPTOR INHIBITORS | GENENTECH, INC. (US) | 2003-07-30 | — | — | EP | claimed |
| US-20020035104-A1 | Integrin receptor inhibitors | GENENTECH, INC. | 2002-03-21 | — | — | US | claimed |
| WO-2002016313-A2 | INTEGRIN RECEPTOR INHIBITORS | GENENTECH, INC. (US) | 2002-02-28 | — | — | WO | claimed |
| US-7265146-B2 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20050187284-A1 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| US-6933314-B2 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2005-08-23 | — | — | US | disclosed |
| US-20040077693-A1 | Integrin receptor inhibitors | GENENTECH, INC. | 2004-04-22 | — | — | US | disclosed |
| US-6706753-B2 | 2-AMINO-FLUORENE DERIVATIVES USEFUL FOR PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH ALPHA 4 INTERGRINS OR THEIR LIGANDS | GENENTECH, INC. | 2004-03-16 | — | — | US | disclosed |
| EP-1330430-A2 | INTEGRIN RECEPTOR INHIBITORS | GENENTECH, INC. (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20030100599-A1 | 2-amino-fluorene derivatives useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with alpha 4 intergrins or their ligands | GENENTECH, INC. | 2003-05-29 | — | — | US | disclosed |
| US-20020035104-A1 | Integrin receptor inhibitors | GENENTECH, INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2002016313-A2 | INTEGRIN RECEPTOR INHIBITORS | GENENTECH, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077693-A1 | Integrin receptor inhibitors | ITGB1, ITGA1, ITGA4 | ESR1 1516/4885ESR2 841/4885MEN1 2727/4885 |
| US-20020035104-A1 | Integrin receptor inhibitors | ITGB1, ITGA1, ITGA4 | ESR1 1516/4885ESR2 841/4885MEN1 2727/4885 |
| US-20050187284-A1 | Integrin receptor inhibitors | ITGA4, ITGB4, ITGB1 | ESR1 1137/4885ESR2 783/4885MEN1 3342/4885 |
| US-20030100599-A1 | 2-amino-fluorene derivatives useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with alpha 4 intergrins or their ligands | ITGA1, ITGA2, ITGB1 | ESR1 1439/4885ESR2 573/4885MEN1 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.